CC-410

CC-410 potently inhibits human NNMT activity in HEK293 cells with an IC₅₀ of 1.6 μM^[1].
CC-410 is highly specific for NNMT, showing only weak inhibition of PRMT3, SET1b Complex, and SMYD2 at concentrations far above its NNMT IC₅₀^[1].
CC-410 (1-25 μM; 48 h) exhibits minimal cytotoxicity in 3T3-L1 pre-adipocytes at concentrations up to 25 μM^[1].
CC-410 (5-25 μM) impairs terminal adipogenesis in 3T3-L1 pre-adipocytes when administered during the early phase of differentiation, with 25 μM causing an ~80% reduction in lipid accumulation, but has no effect when administered after the early phase^[1].
CC-410 (25 μM) impairs terminal adipogenesis in C3H10T1/2 mouse embryonic stem cell precursor cells when administered during the early phase or continuously throughout differentiation, confirming a cell-type-independent mechanism^[1].
CC-410 impairs glucocorticoid-mediated pre-adipocyte priming in 3T3-L1 cells, blocking terminal adipogenesis when administered during Dexamethasone (HY-14648) stimulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.